Volume 23 Issue 1, January 2026

Cover caption: On this cover, YDJC, an IBD susceptibility gene of IBD, is portrayed as a sentinel molecule that suppresses SREBP2-driven cholesterol biosynthesis in CD4⁺ T cells. By limiting cholesterol production, YDJC prevents excessive Th1 cell activation and proinflammatory cytokine release, thereby maintaining immune homeostasis in the intestinal mucosa, and pointing to a novel therapeutic target for IBD.

Refer to: YDJC restrains Th1 cell differentiation by blocking SREBP2-mediated cholesterol biosynthesis to alleviate mucosal inflammation in inflammatory bowel disease. pp:15–30.